Altimmune Stock Investor Sentiment

ALT Stock  USD 3.86  0.12  3.02%   
Slightly above 57% of Altimmune's investor base is looking to short. The analysis of the overall investor sentiment regarding Altimmune suggests that many traders are alarmed. Altimmune's investing sentiment can be driven by a variety of factors including economic data, Altimmune's earnings reports, geopolitical events, and overall market trends.

Comfort Level 43

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Altimmune's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Altimmune.

Altimmune Historical Sentiment

Although Altimmune's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Altimmune, such as negative comments on social media and news outlets, may cause fear in the market and push Altimmune's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Altimmune.

Altimmune Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Altimmune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Altimmune Historical Investor Sentiment

Investor biases related to Altimmune's public news can be used to forecast risks associated with an investment in Altimmune. The trend in average sentiment can be used to explain how an investor holding Altimmune can time the market purely based on public headlines and social activities around Altimmune. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Altimmune's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Altimmune and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Altimmune news discussions. The higher the estimate score, the more favorable the investor's outlook on Altimmune.

Altimmune Maximum Pain Price Across March 20th 2026 Option Contracts

Altimmune's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Altimmune close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Altimmune's options.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Altimmune's Stock prices. Below is the latest headlines and news related to Altimmune Stock. Current markets are slightly bullish. About 59% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Altimmune that are available to investors today. This information is accessible both publicly - through Altimmune's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Altimmune-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Altimmune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Altimmune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Altimmune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Altimmune alpha.

Altimmune Largest EPS Surprises

Earnings surprises can significantly impact Altimmune's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-08-12
2025-06-30-0.31-0.270.0412 
2022-08-11
2022-06-30-0.47-0.420.0510 
2025-11-06
2025-09-30-0.27-0.210.0622 
2020-05-13
2020-03-31-0.32-0.260.0618 
2023-02-28
2022-12-31-0.5-0.430.0714 
2023-05-11
2023-03-31-0.48-0.40.0816 
View All Earnings Estimates
a minute ago at finance.yahoo.com         
Europe B2B Car Subscription Market Outlook 2033 Valuation Set to Reach US 4,174.46 Million as De-Ris...
Yahoo News
2 days ago at thelincolnianonline.com         
Altimmune Director Acquires 51,250.00 in Stock
news
3 days ago at thelincolnianonline.com         
Altimmune Director Buys 51,625.00 in Stock
news
few days ago at globenewswire.com         
Black Masterbatches Market Valuation to Surpass US 4,865.2 Million By 2035 Astute Analytica
Macroaxis News: globenewswire.com
few days ago at globenewswire.com         
Acquisition by Gill John of 12500 shares of Altimmune at 4.1 subject to Rule 16b-3
Macroaxis News: globenewswire.com
few days ago at globenewswire.com         
Mono-Ethylene Glycol Market to Hit Valuation of US 54.56 billion by 2035 Astute Analytica
Macroaxis News: globenewswire.com
few days ago at finance.yahoo.com         
Japan IT Services Market Valuation is Projected to Reach US 231.93 Billion By 2035 Astute Analytica
Yahoo News
few days ago at globenewswire.com         
Japan IT Services Market Valuation is Projected to Reach US 231.93 Billion By 2035 Astute Analytica
Macroaxis News: globenewswire.com
few days ago at globenewswire.com         
Acquisition by Durso Jerome Benedict of 12500 shares of Altimmune at 4.1255 subject to Rule 16b-3
Macroaxis News: globenewswire.com
few days ago at finance.yahoo.com         
Mono-Ethylene Glycol Market to Hit Valuation of US 54.56 billion by 2035 Astute Analytica
Yahoo News
few days ago at globenewswire.com         
Sodium Carbonate Market Set to Reach US 32.9 Billion by 2035 as Chinas Solar Glass Expansion Forces ...
Macroaxis News: globenewswire.com
over a week ago at globenewswire.com         
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b...
Macroaxis News: globenewswire.com
over a week ago at benzinga.com         
Altimmunes MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks
benzinga news
over a week ago at seekingalpha.com         
Altimmune posts mid-stage trial data for MASH drug
seekingalpha News
over a week ago at finance.yahoo.com         
Altimmunes drug for a type of liver disease shows benefits in mid-stage study
Yahoo News
There is far too much social signal, news, headlines, and media speculation about Altimmune that are available to investors today. This information is accessible both publicly - through Altimmune's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Altimmune-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Altimmune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Altimmune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Altimmune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Altimmune alpha.

Altimmune Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Vipin Garg of 26775 shares of Altimmune subject to Rule 16b-3
10/10/2025
2
Acquisition by Vipin Garg of 18950 shares of Altimmune subject to Rule 16b-3
11/21/2025
3
China Myopia Control Lenses Market Set to Hit Valuation of US 935.60 Million by 2033 Astute Analytica
12/04/2025
4
Disposition of 7231 shares by Vipin Garg of Altimmune at 6.64 subject to Rule 16b-3
12/05/2025
5
Location Based Services Market Set to Reach US 547.92 Billion by 2033 as Breakthroughs in GNSS and RTK Precision Accelerate High-Accuracy Adoption Astute Analyt...
12/08/2025
6
Disposition of 11701 shares by Vipin Garg of Altimmune at 7.0 subject to Rule 16b-3
12/12/2025
7
Thin-Film Electrode Market to Reach US 1,595.3 Million By 2035 Astute Analytica
12/15/2025
8
Fire Truck Market Set to Reach US 17.5 Billion by 2035 as Rising Municipal Capital Spending and Inflationary Pricing Drive Fleet Replacement Cycles Says Astute ...
12/17/2025
9
Vehicle to Grid Market Set to Reach US 65.84 Billion by 2035 Astute Analytica
12/18/2025
10
Altimmunes MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks
12/19/2025
11
Japan IT Services Market Valuation is Projected to Reach US 231.93 Billion By 2035 Astute Analytica
12/22/2025
12
Black Masterbatches Market Valuation to Surpass US 4,865.2 Million By 2035 Astute Analytica
12/23/2025

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.